OncoTherapy Science Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

OncoTherapy Science şirketinin toplam hissedar öz sermayesi ¥999.0M ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥1.5B ve ¥549.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥1.10b
Eşitlik	JP¥999.00m
Toplam yükümlülükler	JP¥549.00m
Toplam varlıklar	JP¥1.55b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 30O 'nin kısa vadeli varlıkları ( ¥1.5B ) kısa vadeli yükümlülüklerini ( ¥421.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 30O şirketinin kısa vadeli varlıkları ( ¥1.5B ) uzun vadeli yükümlülüklerini ( ¥128.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 30O borçsuzdur.

Borcun Azaltılması: 30O son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 30O şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 17 oranında tarihsel oranda büyümeye devam ederse 30O un bir yıldan az nakit akışı süresi vardır.

OncoTherapy Science Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)

OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024

New major risk - Financial data availability

First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)

OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)

OncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024

OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor

Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)

OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)

OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)

OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Shareholder dilution

New major risk - Share price stability

Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)

OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023

Less than half of directors are independent

Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)

OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)

OncoTherapy Science, Inc. to Report Q2, 2023 Results on Nov 04, 2022

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)

OncoTherapy Science, Inc. to Report Q1, 2023 Results on Aug 05, 2022

Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)

OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022

Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)

OncoTherapy Science, Inc. to Report Fiscal Year 2022 Results on May 06, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

OncoTherapy Science, Inc. to Report Q3, 2022 Results on Feb 04, 2022

Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)

Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)

Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)

OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm

OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding

Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)

OncoTherapy Science, Inc. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day low: €0.83

New 90-day low: €0.96

Second quarter 2021 earnings released: JP¥2.48 loss per share

New 90-day high: €1.47

OncoTherapy Science, Inc. to Report Q1, 2021 Results on Aug 07, 2020

First quarter earnings released

First quarter earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin